C4 Therapeutics (CCCC): Can the Stock Reach $7?

Key Takeaways

• The selected price target is $7, roughly 81% above the latest close of $3.87 and about 35% above the 52-week high of $5.17.
• Wall Street support is a key bullish factor: the low end of current analyst price targets clusters near $6 to $7, with consensus estimates well above that level.
• The biggest obstacles are clinical-stage execution risk, ongoing losses, and the fact that pivotal Phase 2 data is not expected until the second half of 2027.
• Important technical levels include support near $3.40–$3.50 and major resistance at the 52-week high of $5.17, which must be cleared before $7 becomes realistic.
• Overall, $7 is an ambitious but not unrealistic 12-to-24-month scenario that depends heavily on clinical data and partnership progress.

Why $7 Remains a Key Target

The $7 level is not an arbitrary round number. It sits near the low end of Wall Street’s published 12-month price targets for the stock and represents the first major technical objective above the stock’s recent peak of $5.17. Because C4 Therapeutics, Inc. (CCCC) has spent much of the past year recovering from a low of $1.69, a move to $7 would confirm that the market is treating the company as a credible late-stage oncology story rather than a speculative micro-cap.

C4 Therapeutics’ Focus and Market Standing

C4 Therapeutics, Inc. (CCCC) develops medicines that use the body’s natural protein-recycling system to degrade disease-causing proteins. Its lead program, cemsidomide, is an oral degrader targeting IKZF1/3 proteins in relapsed/refractory multiple myeloma. The company is enrolling the Phase 2 MOMENTUM trial, with initial response-rate data expected in the second half of 2027, and is also testing cemsidomide in combination with elranatamab in a Phase 1b study.

Financially, the company remains pre-profit. Second-quarter 2026 revenue was $6.6 million, with a net loss of $23.6 million. However, cash, cash equivalents and marketable securities stood at approximately $300.4 million as of June 30, 2026, which management expects will fund operations into 2028. The company also received a $20 million upfront payment from Roche in May 2026 under a degrader-antibody conjugate collaboration.

Factors That Could Support Higher Prices

The strongest argument for a move toward $7 is that several Wall Street firms already value the stock at or above that level. Barclays and Guggenheim have published $7 targets, while Wells Fargo, Jefferies and others have targets ranging from $10 to $14. That suggests professional analysts are pricing in meaningful clinical and partnership upside that the current share price does not yet fully reflect. From what I see, this analyst backing provides a solid foundation for upside if execution stays on track.

The Roche collaboration also provides external validation of C4 Therapeutics’ platform and a source of non-dilutive funding. Combined with a cash runway into 2028, this reduces the near-term risk of a forced capital raise. In addition, reported short interest near 23% of the float as of mid-July 2026 could amplify an upward move if positive news forces short sellers to cover. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Risks That Could Hold the Stock Back

The central risk is clinical. Cemsidomide is still in Phase 2, and the next major efficacy readout is not expected until the second half of 2027. Until then, the stock may lack the kind of binary, data-driven catalyst that typically powers large biotech re-ratings.

The company also remains deeply unprofitable, with revenue expected to decline in 2026 as collaboration payments fluctuate. During the second quarter, C4 Therapeutics raised approximately $33.5 million through its at-the-market program, a reminder that equity dilution remains an ongoing possibility. Finally, the stock must first break decisively above its 52-week high of $5.17, a level that has already marked the upper boundary of the recent recovery.

Analyst Views and Key Technical Levels

Analyst opinion is broadly constructive but varies widely. Depending on the data provider, the consensus 12-month stock price target ranges from about $7.75 to $13.33, with individual targets stretching from $6 or $7 on the low end to $30 on the high end. The dispersion reflects genuine uncertainty about the value of a clinical-stage platform.

From a technical analysis perspective, the stock has established support in the $3.40–$3.50 zone during recent consolidation. The first major resistance level is the 52-week high near $5.17. A decisive close above that level would open the path toward $7, while failure to hold current support would keep the stock rangebound.

Putting It All Together

A move to $7 appears achievable over a 12-to-24-month horizon, but it is not a near-term certainty. The strongest supporting factors are a multiyear cash runway, analyst targets at or above $7, and the validation provided by the Roche collaboration. The primary risks are binary clinical outcomes, limited catalysts before 2027, ongoing losses, and potential dilution. Investors should monitor cemsidomide trial progress, partnership milestones, and the stock’s ability to hold support near $3.40–$3.50 before challenging the $5.17 resistance level.

Monitoring with AI Daily Buy/Sell Signals

In my own process, I often turn to Tickeron’s AI Daily Buy/Sell Signals when tracking names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical patterns and data-driven models. It helps me stay objective on momentum shifts and potential entry or exit points without relying solely on manual chart review. This approach has proven useful for confirming whether setups are gaining traction ahead of key levels.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume